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Abstract: The study aims to investigate the performance characteristics of the enantiomers of 11C-Me-
NB1, a recently reported PET imaging probe that targets the GluN2B subunit of N-methyl-d-aspartate
(NMDA) receptors. Methods: Reference compound Me-NB1 (inhibition constant for hGluN1/GluN2B,
5.4 nM) and the phenolic precursor were prepared via multistep synthesis. Following chiral resolution
by high-performance liquid chromatography, enantiopure precursor compounds, (R)-NB1 and (S)-NB1,
were labeled with 11C and validated in rodents using in vitro/ex vivo autoradiography, PET experiments,
and dose-response studies. To illustrate the translational relevance, (R)- 11C-Me-NB1 was validated in
autoradiographic studies using postmortem human GluN2B-rich cortical and GluN2B-deficient cerebel-
lar brain slices. To determine target engagement, receptor occupancy was assessed at different plasma
concentrations of CP101,606, a GluN2B receptor antagonist. Results: The radiosynthesis of (R)- and
(S)- 11C-Me-NB1 was accomplished in 42% ± 9% (decay-corrected) radiochemical yields. Molar ac-
tivity ranged from 40 to 336 GBq/฀mol, and an excellent radiochemical purity of greater than 99% was
achieved. Although (R)- 11C-Me-NB1 displayed heterogeneous accumulation with high selectivity for the
GluN2B-rich forebrain, (S)- 11C-Me-NB1 revealed a homogeneous distribution across all brain regions in
rodent brain autoradiograms and predominantly exhibited ฀1-receptor binding. Similar to rodent brain,
(R)- 11C-Me-NB1 showed in postmortem human brain tissues higher binding in the cortex than in the
cerebellum. Coincubation of the GluN2B-antagonist CERC-301 (1 ฀M) reduced cortical but not cerebel-
lar binding, demonstrating the specificity of (R)- 11C-Me-NB1 binding to the human GluN2B-containing
NMDA receptor. In vivo specificity of (R)- 11C-Me-NB1 in the GluN2B-expressing cortex, striatum, tha-
lamus, and hippocampus was demonstrated by PET imaging in rodents. Applying GluN2B-antagonist
eliprodil, an evident dose-response behavior was observed with (R)- 11C-Me-NB1 but not with (S)- 11C-
Me-NB1. Our findings further underline the tightrope walk between GluN2B- and ฀1-receptor-targeted
imaging, illustrated by the entirely different receptor binding behavior of the 2 radioligand enantiomers.
Conclusion: (R)- 11C-Me-NB1 is a highly selective and specific PET radioligand for imaging the GluN2B
subunit of the NMDA receptor. The entirely different receptor binding behavior of (R)- 11C-Me-NB1
and (S)- 11C-Me-NB1 raises awareness of a delicate balance that is underlying the selective targeting of
either GluN2B-carrying NMDA or ฀1-receptors.
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Supplemental Figure 2: Chiral HPLC separation of Me-NB1 and NB1 under isocratic normal phase conditions 
(hexane/isopropanol 8:2). A. Semipreparative chromatogram after chiral resolution of (rac)-NB1. C. Semipreparative 


















Supplemental Figure 3: A. Radiolabeling of (R)- and (S)-11C-Me-NB1 was achieved by treatment of the phenolic precursor in 
analogy to the procedure recently published by our group . B. Quality control of formulated tracer by UV- and radio-trace. C. 















Supplemental Figure 4: Representative autoradiograms of (R)-11C-Me-NB1 and (S)-11C-Me-NB1 on coronal mouse brain 
sections. The binding of (R)-11C-Me-NB1  was heterogeneous and GluN2B-specific while (S)-11C-Me-NB1 showed considerable 
1R binding. The blocking studies revealed selectivity of the R-enantiomer over 1R. In contrast, the S-enantiomer exhibited 































Supplemental Figure 5: Molecular dynamics simulation of the most stable (R)-Me-NB1 and (S)-Me-NB1 binding modes and 
stability of the predicted hydrogen-bond interactions. A. (R)-Me-NB1 interactions were observed between the ligand NH-group 
and glutamine 110 as well as the ligand OH-group and both glutamate 106 and glutamine 110 of the GluN2B subunit. Hydrogen 
bonds were maintained during MD. B. (S)-Me-NB1 interactions were observed between the ligand NH-group and glutamine 110 
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as well as the ligand OH-group and glutamate 106. No interaction between ligand OH-group and glutamine 110 was predicted. 
Hydrogen bonds were not maintained during MD.  
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Supplemental Figure 6: Molecular dynamics simulation of the less stable binding modes of (R)-Me-NB1 (A and B) and (S)-Me-












Supplemental Table 1: Calculated MM-GBSA binding free energies (kcal/mol) for the two most stable (R)- and (S)-Me-NB1 
binding modes using different GB models. Standard error of the mean (SEM) is given in brackets. 
 GB1 GB2 GB5 GB8 
(R)-Me-NB1 -59.99 (0.43) -56.38 (0.44) -60.56 (0.47) -51.61 (0.58) 































Supplemental Figure 7: Metabolite study with (R)-11C-Me-NB1 was performed in male Wistar rats. A. Radio-UPLC analysis of 
the brain samples after 15 and 45 min post injection revealed the presence of parent tracer. No radiometabolite was detected. B. 
Radio-TLC analysis confirmed the radio-UPLC findings for the brain samples. Plasma data at 45 min post injection indicate that 






























Supplemental Figure 8: Receptor occupancy studies with (R)-11C-Me-NB1 and GluN2B-antagonist CP101,606 in male Wistar 
rats. A. Target occupancy was studied upon bolus injections, followed by infusion of CP101,606 to maintain constant plasma 
levels. B. Target occupancy was studied upon bolus injection only, without further infusion of CP101,606. The following 
equations were used to calculate receptor occupancies: AUC = (bmax - bmin) * D50/(D + D50) + bmin; RO = (bmax - 
AUC)/(bmax - bmin ) * 100, where AUC is the area under the curve of the respective PET scan, D50 is the dose required for 50 % 
receptor occupancy, D is the actual dose, RO is the receptor occupancy in % and bmax as well as bmin are the maximum and 

























Supplemental Figure 9: PET experiments with (R)-11C-Me-NB1 and GluN2B-antagonist CERC-301 and EVT 101 as blocking 












Supplemental Table 2: Organ biodistribution of (R)-11C-Me-NB1 in Wistar rats (n=4), reported as averaged % normalized 
injected dose per gram body weight ± standard deviation. Twenty-four male Wistar rats were tail-vein injected with (R)-11C-Me-
NB1 (13 – 30 MBq, 0.5 – 4.9 nmol/kg) and sacrificed by decapitation under isoflurane anaesthesia (induced 5 min before 
decapitation) at the time points 5, 15, 30, 45 and 60 min p.i. (n = 4 for every time point). Additionally, a blockade study was 
conducted by injection of 2 mg/kg eliprodil in an aqueous vehicle of pH 7.0 containing glucose (5 %), NaCl (0.45 %) and citric 
acid (1 mM) shortly before the radiotracer and rats have been euthanized at 15 min post injection. The same vehicle was injected 
into baseline animals shortly before tracer administration. Organs were dissected, weighed and the radioactivity was measured 




















Supplemental Table 3: Regional biodistribution of (R)-11C-Me-NB1 in the Wistar rat brain (n=4), reported as averaged % 
normalized injected dose per gram body weight ± standard deviation. 
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